<bill session="107" type="h" number="386" updated="2013-07-14T18:57:05-04:00">
  <state datetime="2001-01-31">REFERRED</state>
  <status>
    <introduced datetime="2001-01-31"/>
  </status>
  <introduced datetime="2001-01-31"/>
  <titles>
    <title as="introduced" type="short">Orphan Drug Program Improvement Act of 2001</title>
    <title as="introduced" type="official">To amend the Federal Food, Drug, and Cosmetic Act with respect to orphan drugs.</title>
  </titles>
  <sponsor id="400404"/>
  <cosponsors>
    <cosponsor id="400099" joined="2001-02-28"/>
    <cosponsor id="400507" joined="2001-02-27"/>
    <cosponsor id="400394" joined="2001-03-06"/>
  </cosponsors>
  <actions>
    <action state="REFERRED" datetime="2001-01-31">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2001-02-14">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Commerce"/>
    <term name="Drug approvals"/>
    <term name="Labeling"/>
    <term name="Law"/>
    <term name="Licenses"/>
    <term name="Orphan drugs"/>
  </subjects>
  <amendments/>
  <summary>1/31/2001--Introduced.
Orphan Drug Program Improvement Act of 2001 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services, respecting application approval or licensing, to conform the designation of a drug for a rare disease or condition (orphan drug) to reflect such drug's approved labeling.Exempts clinically superior subsequent orphan drugs from the seven-year prohibition of approval respecting a previously approved or licensed drug.</summary>
</bill>
